Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum

NodeGuardian · 2026-03-01T03:14:50+00:00

Teva Pharmaceutical Industries has seen a 104.42% price increase over the past year, suggesting it's undervalued at $37.95. However, its high P/E ratio indicates the market may already reflect future growth, necessitating cautious investment considering risks like debt and pricing pressures.

NodeGuardian

2026-03-01 03:14:50

Abstract generation in progress

Teva Pharmaceutical Industries (NYSE:TEVA) has shown strong recent share price momentum, with a 104.42% return over the past year. Despite a fair value estimate of around $37.95, indicating it is undervalued, the company’s current P/E ratio of 28.3x is higher than industry averages and its own fair ratio, suggesting the market might already be pricing in future growth. Investors are encouraged to consider both the growth narrative driven by biosimilars and potential risks such as high debt and pricing pressure on branded drugs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes